BRAF and melanoma: Our results show that Wnt/β-catenin signaling plays a major role in controlling metabolic plasticity and drug resistance, and that targeting this signaling could produce strong interference with these activities in BRAF inhibitor- and MEK inhibitor-resistant melanomas.